论文部分内容阅读
目的:观察奥卡西平(OCBZ)治疗癫痫的疗效、耐受性和安全性。方法:对36例癫痫患者采用单用和添加奥卡西平治疗,其中19例未经过抗癫痫治疗进入单药治疗组,17例曾使用一线抗癫痫药物无效而进入添加治疗组,两组服用奥卡西平疗程均达6个月。成人起始剂量为剂量为0.15g,qn,维持剂量600～1200 mg.d~(-1),最大未超过1.5g;儿童按10 mg·kg~(-1)·d~(-1),分两次服用,增加剂量每周不超过10 mg·kg~(-1)·d~(-1)。分两次服用,最大不超过30 mg·kg~(-1)·d~(-1)。分析两组6月以上的疗效、耐受性和安全性。结果:本组总有效率为88.9%,完全控制为36.1%;其中单药治疗组控制率42.1%,总有效率为94.7%,添加治疗组控制率为29.4%,总有效率为82.4%。最常见的不良反应为头昏、头痛、嗜睡、皮疹、纳差等,单治组不良反应总发生率为31.6%,添加治疗组不良反应发生率为58.8%。结论:奥卡西平治疗癫痫安全、稳定、有效。
Objective: To observe the efficacy, tolerability and safety of oxcarbazepine (OCBZ) in the treatment of epilepsy. Methods: Thirty-six patients with epilepsy were treated with oxcarbazepine alone or in combination. Among them, 19 patients entered the monotherapy group without anti-epilepsy treatment, and 17 patients who used the first-line antiepileptic drugs failed to enter the addition therapy group. Caxipine treatment course up to 6 months. Adult initial dose of 0.15g, qn, maintenance dose of 600 ~ 1200 mg.d ~ (-1), the maximum did not exceed 1.5g; children according to 10 mg · kg -1 d -1, , Take it in two times and increase the dosage not more than 10 mg · kg -1 · d -1 every week. Take two times, the maximum does not exceed 30 mg · kg -1 (-1) d -1. The efficacy, tolerability and safety of the two groups over June were analyzed. Results: The total effective rate was 88.9% and the complete control was 36.1%. The control rate of single drug treatment group was 42.1% and the total effective rate was 94.7%. The control group was 29.4% and the total effective rate was 82.4%. The most common adverse reactions were dizziness, headache, drowsiness, rash, anorexia, etc. The overall incidence of adverse reactions was 31.6% in monotherapy group and 58.8% in adverse drug treatment group. Conclusion: Oxcarbazepine is safe, stable and effective in the treatment of epilepsy.